PTC Therapeutics PTCT US — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's us — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's US — revenue?
- PTC Therapeutics (PTCT) reported US — revenue of $136.52M in Q1 2026.
- How has PTC Therapeutics's US — revenue changed year-over-year?
- PTC Therapeutics's US — revenue increased by 185.7% year-over-year, from $47.79M to $136.52M.
- What is the long-term trend for PTC Therapeutics's US — revenue?
- Over 4 years (2021 to 2025), PTC Therapeutics's US — revenue has grown at a -4.0% compound annual growth rate (CAGR), from $297.01M to $252.18M.
- What does US — revenue mean?
- This metric represents the total revenue generated from contracts with customers within the United States, excluding any sales-based taxes collected on behalf of government authorities. It serves as a primary indicator of the company's core commercial performance and market penetration in the US region. Tracking this figure allows investors to assess the underlying demand for the company's therapeutic products without the volatility of tax-related accounting adjustments.